Related references
Note: Only part of the references are listed.Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis
Marc Arbyn et al.
LANCET GLOBAL HEALTH (2020)
Estimation of clinical trial success rates and related parameters
Chi Heem Wong et al.
BIOSTATISTICS (2019)
Global human papilloma virus vaccine implementation: An update
Sasidharanpillai Sabeena et al.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (2018)
Cervical cancer vaccine controversy in India
Manjulika Das
LANCET ONCOLOGY (2018)
Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study
Rengaswamy Sankaranarayanan et al.
VACCINE (2018)
Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study
Dimitrios Gouglas et al.
LANCET GLOBAL HEALTH (2018)
Economics of the Pharmaceutical Industry
Darius N. Lakdawalla
JOURNAL OF ECONOMIC LITERATURE (2018)
Worldwide burden of cancer attributable to HPV by site, country and HPV type
Catherine de Martel et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval
Vinay Prasad et al.
JAMA INTERNAL MEDICINE (2017)
Key cost drivers of pharmaceutical clinical trials in the United States
Aylin Sertkaya et al.
CLINICAL TRIALS (2016)
Manufacturing costs of HPV vaccines for developing countries
Chaevia Clendinen et al.
VACCINE (2016)
Market outcomes and dynamic patent buyouts
Alberto Galasso et al.
INTERNATIONAL JOURNAL OF INDUSTRIAL ORGANIZATION (2016)
Recent progress in vaccination against human papillomavirus-mediated cervical cancer
Sara J. McKee et al.
REVIEWS IN MEDICAL VIROLOGY (2015)
Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines: Patent landscaping and perspectives of developing country vaccine manufacturers
Subhashini Chandrasekharan et al.
VACCINE (2015)
Update on prevention and screening of cervical cancer
Shaniqua L. McGraw et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2014)
Promotion of Prescription Drugs to Consumers and Providers, 2001-2010
Rachel Kornfield et al.
PLOS ONE (2013)
Risk in Vaccine Research and Development Quantified
Esther S. Pronker et al.
PLOS ONE (2013)
The Patient-Consumer-Advocate Nexus
Samantha D. Gottlieb
MEDICAL ANTHROPOLOGY QUARTERLY (2013)
Neglected infectious diseases: are push and pull incentive mechanisms suitable for promoting drug development research?
Frank Mueller-Langer
HEALTH ECONOMICS POLICY AND LAW (2013)
Evidence-based Screening, Early Diagnosis and Treatment Strategy of Cervical Cancer for National Policy in Low-resource countries: Example of India
Upma Saxena et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2012)
Too Fast or Not Too Fast: The FDA's Approval of Merck's HPV Vaccine Gardasil
Lucija Tomljenovic et al.
JOURNAL OF LAW MEDICINE & ETHICS (2012)
Potential overestimation of HPV vaccine impact due to unmasking of non-vaccine types: Quantification using a multi-type mathematical model
Yoon Hong Choi et al.
VACCINE (2012)
New Decade of Vaccines 3 Vaccine production, distribution, access, and uptake
Jon Smith et al.
LANCET (2011)
Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males
Anna R. Giuliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Current Status of Human Papillomavirus Vaccines
Barbara Ma et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2010)
Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India
Swathi Padmanabhan et al.
NATURE BIOTECHNOLOGY (2010)
ALFRED MARSHALL LECTURE INTELLECTUAL PROPERTY RIGHTS PROTECTION IN DEVELOPING COUNTRIES: THE CASE OF PHARMACEUTICALS
Pinelopi Koujianou Goldberg
JOURNAL OF THE EUROPEAN ECONOMIC ASSOCIATION (2010)
Epidemiology and prevention of human papillomavirus and cervical cancer in sub-Saharan Africa: a comprehensive review
Karly S. Louie et al.
TROPICAL MEDICINE & INTERNATIONAL HEALTH (2009)
Estimated research and development costs of rotavirus vaccines
Donald W. Light et al.
VACCINE (2009)
Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia
F. Xavier Bosch et al.
VACCINE (2008)
Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries
Sue J. Goldie et al.
VACCINE (2008)
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Suzanne M. Garland et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Worldwide distribution of human papillomavirus types in cytologically normal women in the international Agency for Research on Cancer HPV prevalence surveys:: a pooled analysis
GM Clifford et al.
LANCET (2005)
Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US - Analytic framework and review of the literature
RP Insinga et al.
PHARMACOECONOMICS (2005)